These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23558218)

  • 1. Erythropoietin and heart failure: the end of a promise?
    Kleijn L; Westenbrink BD; van der Meer P
    Eur J Heart Fail; 2013 May; 15(5):479-81. PubMed ID: 23558218
    [No Abstract]   [Full Text] [Related]  

  • 2. Darbapoetin alfa does not help adults with heart failure and anaemia.
    BMJ; 2013 Mar; 346():f1626. PubMed ID: 23487165
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of erythropoietin in heart failure management.
    Caiola K; Cheng JW
    Ann Pharmacother; 2004 Dec; 38(12):2145-9. PubMed ID: 15494385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemodilution is a mechanism of anaemia in patients with heart failure.
    Prakash ES
    Eur J Heart Fail; 2013 Sep; 15(9):1074. PubMed ID: 23883650
    [No Abstract]   [Full Text] [Related]  

  • 5. The etiology of anemia in heart failure. Preface.
    Agarwal AK; Katz SD; Singh AK
    Heart Fail Clin; 2010 Jul; 6(3):xvii-xviii. PubMed ID: 20630400
    [No Abstract]   [Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agents in kidney and cardiac disease.
    Fluck R
    Br J Hosp Med (Lond); 2006 Oct; 67(10):533-7. PubMed ID: 17069130
    [No Abstract]   [Full Text] [Related]  

  • 7. Haemodilution is a mechanism of anaemia in patients with heart failure: reply.
    Westenbrink BD; Kleijn L; van der Meer P
    Eur J Heart Fail; 2013 Sep; 15(9):1075-6. PubMed ID: 23960086
    [No Abstract]   [Full Text] [Related]  

  • 8. Summaries of nursing care-related systematic reviews from the Cochrane library: erythropoiesis-stimulating agents for anemia in chronic heart failure patients.
    Barrett D
    J Cardiovasc Nurs; 2010; 25(5):381-2. PubMed ID: 20714234
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythropoiesis-stimulating agents in heart failure: no proof of effectiveness or proof of no effectiveness?
    Messori A; Fadda V; Maratea D; Trippoli S
    Eur J Heart Fail; 2013 Aug; 15(8):944-5. PubMed ID: 23884182
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of anemia with darbepoetin alfa in heart failure.
    Abraham WT; Anand IS; Klapholz M; Ponikowski P; Scarlata D; Wasserman SM; van Veldhuisen DJ
    Congest Heart Fail; 2010; 16(3):87-95. PubMed ID: 20557327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
    Lappin TR; Maxwell AP; Johnston PG
    Oncologist; 2007 Apr; 12(4):362-5. PubMed ID: 17470677
    [No Abstract]   [Full Text] [Related]  

  • 12. Erythropoietin: high profile, high scrutiny.
    Crawford J
    J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
    [No Abstract]   [Full Text] [Related]  

  • 13. Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).
    McMurray JJ; Anand IS; Diaz R; Maggioni AP; O'Connor C; Pfeffer MA; Solomon SD; Tendera M; van Veldhuisen DJ; Albizem M; Cheng S; Scarlata D; Swedberg K; Young JB;
    Eur J Heart Fail; 2013 Mar; 15(3):334-41. PubMed ID: 23329651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correcting anemia in heart failure: the efficacy and safety of erythropoiesis-stimulating agents.
    Lawler PR; Filion KB; Eisenberg MJ
    J Card Fail; 2010 Aug; 16(8):649-58. PubMed ID: 20670844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
    Ponikowski P; Anker SD; Szachniewicz J; Okonko D; Ledwidge M; Zymlinski R; Ryan E; Wasserman SM; Baker N; Rosser D; Rosen SD; Poole-Wilson PA; Banasiak W; Coats AJ; McDonald K
    J Am Coll Cardiol; 2007 Feb; 49(7):753-62. PubMed ID: 17306703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer- and treatment-related anemia.
    Rodgers GM; Cella D; Chanan-Khan A; Chesney C; Cleeland C; Coccia PF; Demetri GD; Djulbegovic B; Garst JL; Gore M; Kraut EH; Lin WC; Millenson M; Mock V; Reinke D; Rosenthal J; Sabbatini P
    J Natl Compr Canc Netw; 2005 Nov; 3(6):772-89. PubMed ID: 16316613
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure.
    Kourea K; Parissis JT; Farmakis D; Paraskevaidis I; Panou F; Filippatos G; Kremastinos DT
    Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):365-9. PubMed ID: 18525396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia in chronic heart failure.
    Drakos SG; Anastasiou-Nana MI; Malliaras KG; Nanas JN
    Congest Heart Fail; 2009; 15(2):87-92. PubMed ID: 19379455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilizing quality of life as a factor in treatment choices for chemotherapy-induced anemia.
    Koopman W; Iakiri S
    J Support Oncol; 2005; 3(6 Suppl 4):20-1. PubMed ID: 16355554
    [No Abstract]   [Full Text] [Related]  

  • 20. Should erythropoietin treatment in chronic heart failure be haemoglobin targeted?
    Kleijn L; de Boer RA; Voors AA
    Eur J Heart Fail; 2010 Mar; 12(3):215-6. PubMed ID: 20156936
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.